Project Grant R01AI184584

Award Date 6/10/24
Completion Date 5/31/29
Dollars Obligated $2.1M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This Project Grant award of $1,011,348 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to understand how interactions between Mycobacterium tuberculosis (M.TB) and the human alveolar environment, particularly in people living with HIV, impact the early stages of TB infection. The key objectives are to: 1) Determine how M.TB exposure to alveolar lining fluid from people living with...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $447,009 to the University of Massachusetts to conduct research on the early immune response to Mycobacterium tuberculosis (MTB) infection. The key objectives are to: 1) Categorize alveolar macrophage sensing abilities and defects in responding to MTB pathogen-associated molecular patterns, and screen for novel...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $162,000 in funding to The Washington University to conduct research on the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The goal is to characterize pDC function during MTB infection to identify potential pDC-specific therapeutic targets that could lead to host-directed...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $749,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University for research on the role of macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis. The primary objectives are to: 1) define the role of MDR1 in M.TB survival in macrophages; 2) determine if HSF1 activation or MDR1 inhibition can shorten M.TB sterilization by TB drugs;...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $140,256 to The Washington University to conduct research on how the Mycobacterium tuberculosis (MTB) bacterium promotes its survival within neutrophils. The primary objectives are to elucidate the mechanisms by which the ESX-1 type VII secretion system of MTB dysregulates neutrophil responses to favor the pathogen's...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $1,503,349 to the University of Arkansas for Medical Sciences to conduct research on the ontogeny and metabolism of lung alveolar macrophages and their role in tuberculosis infection. The project aims to determine how the origin and metabolic pathways of these macrophages contribute to their permissiveness to Mycobacterium tuberculosis, and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $451,000.00 to The University of Texas Southwestern Medical Center to develop an "Alveolus on a Chip Model of Non-Tuberculous Mycobacteria Infection". The project aims to leverage a human lung-on-a-chip model to gain insights into the pathogenesis of non-tuberculous mycobacteria (NTM) infections and...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to define the functional role of lung microfold (M) cells in predisposition to influenza-associated pneumococcal invasion and ensuing pneumonia and sepsis. The $342,900 award, spanning September 2024 to September 2026, will support in vitro and in vivo studies to identify the intracellular trafficking mechanisms during pneumococcal transcytosis across airway M cells....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $744,977 to Emory University to conduct research on the role of T cells in protecting against respiratory virus transmission. The research aims to identify the cellular interactions and molecular mechanisms that allow tissue-resident memory T cells (TRM) to rapidly eliminate infected cells and limit viral propagation...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $565,149 to Health Research, Inc. Wadsworth Center Division to conduct research on RNA-based regulatory mechanisms in Mycobacterium tuberculosis (MTB). The primary objectives are to: Define the regulatory interactions of the sRNA MCR11 and its impact on gene expression in MTB. Characterize the roles of RNA-ABMR...

INTERACTION OF MYCOBACTERIUM TUBERCULOSIS WITH UPPER AIRWAY MUCOSAL CELLS - PROJECT SUMMARY THE NASOPHARYNGEAL AND RESPIRATORY MUCOSA REPRESENTS A PRIMARY BARRIER TO INFECTION BY INHALED ORGANISMS. INDEED, THE EARLIEST CONTACT POINT BETWEEN THE AIRWAY PATHOGEN MYCOBACTERIUM TUBERCULOSIS AND THE HUMAN BODY IS THE AIRWAY MUCOSA. AS A RESULT, M. TUBERCULOSIS HAS EVOLVED TO DISSEMINATE BEYOND THE ORAL AND RESPIRATORY MUCOSA TO CAUSE SYSTEMIC DISEASE, THUS ACCOUNTING FOR ITS GLOBAL IMPACT ON HUMAN MORBIDITY AND MORTALITY. LINING THE AIRWAY MUCOSA ARE SPECIALIZED EPITHELIAL CELLS THAT FUNCTION TO TRANSCYTOSE MUCOSAL ANTIGENS FROM THE MUCOSAL SURFACE TO THE BASOLATERAL SPACE. THESE CELLS, KNOWN AS MICROFOLD OR M CELLS, OVERLIE MUCOSAL ASSOCIATED LYMPHATIC TISSUE WHERE MACROPHAGES AND DENDRITIC CELLS AWAIT TO INGEST AND PRESENT ANTIGENS TO B-CELLS AND T-CELLS. WE PREVIOUSLY DEMONSTRATED THAT M. TUBERCULOSIS PENETRATES THE MUCOSA VIA M CELLS BY USING A VIRULENCE FACTOR CALLED ESXA AND A HOST RECEPTOR, SCAVENGER RECEPTOR B1 (SR-B1). HOWEVER, A MAJOR GAP IN OUR UNDERSTANDING OF THE IMPACT OF THIS VERY EARLY EVENT ON THE INTERACTION OF M. TUBERCULOSIS WITH THE AIRWAY IS THAT WE DO NOT FULLY UNDERSTAND M CELL BIOLOGY. HERE, WE WILL APPLY GENETIC, BIOCHEMICAL, IMMUNOLOGIC, TRANSCRIPTOMIC AND ANIMAL APPROACHES TO DETERMINE THE FUNCTIONAL ROLE OF M-CELLS IN MUCOSAL AND SYSTEMIC IMMUNITY AGAINST M. TUBERCULOSIS. THUS, IN THE PROPOSED RESEARCH WE WILL: (1) DETERMINE THE TRANSCRIPTIONAL PROFILES AND FUNCTIONS OF NOVEL GENES OF PRIMARY HUMAN AND MOUSE AIRWAY M CELLS AT A SINGLE CELL LEVEL UNDER BOTH HOMEOSTATIC CONDITIONS AND AFTER EXPERIMENTAL M. TUBERCULOSIS INFECTION, (2) IDENTIFY AND STUDY UNIQUE CELL-CELL INTERACTIONS OF M CELLS WITH THEIR ADJACENT EPITHELIAL AND IMMUNE CELLS, (3) CHARACTERIZE THE MECHANISMS OF BINDING AND TRANSCYTOSIS OF M. TUBERCULOSIS BY AIRWAY M CELLS, (4) DETERMINE THE IMMUNOLOGIC IMPACT OF M. TUBERCULOSIS TRANSCYTOSIS ACROSS AIRWAY M CELLS. THE PROPOSED WORK IS EXPECTED TO IDENTIFY HOW M CELLS BIND AND TRANSCYTOSE M. TUBERCULOSIS AND HOW THIS VERY EARLY EVENT IN THE LIFE CYCLE OF M. TUBERCULOSIS DICTATES THE IMMUNOLOGIC OUTCOME OF INFECTION.

Posted 6/10/24, 12:00 AM